Text Size

Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

This study is currently recruiting participants.
Verified April 2013 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01474772
First received: November 15, 2011
Last updated: April 29, 2013
Last verified: April 2013
History of Changes
  Purpose

The intent of this study is to treat subjects with painful Diabetic Peripheral Neuropathy (DPN) who also have pain on walking and to determine whether or not pregabalin demonstrates improvement relative to placebo on the following: reducing DPN pain, reducing pain on walking, and providing other benefits associated with daily activities and quality of life.


Condition Intervention Phase
Diabetic Peripheral Neuropathy
 Drug: Pregabalin
Other: placebo
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3b Multicenter, Double-Blind, Randomized Cross-Over Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Painful Diabetic Peripheral Neuropathy

Resource links provided by NLM:

Drug Information available for: Pregabalin
U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Reduction in Diabetic Peripheral Neuropathy (DPN) pain [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Reduction in DPN pain on walking [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Responder rate, 30% and 50% improvement in mean pain response [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Brief Pain Inventory-short form [ Time Frame: 14 weks ] [ Designated as safety issue: No ]
  • Daytime activity measured by actigraphy [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Walk-12 [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Norfolk Quality of Life for Diabetic Neuropathy [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Patient Global Impression of Change [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Sleep Interference Rating Scale [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Hospital Anxiety and Depression Scale [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]
  • Euro Quality of Life-5 Dimensions [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 175
Study Start Date: December 2011
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pregabain Drug: Pregabalin
150-300 mg/day given in 3 divided doses as capsules
Other Name: Lyrica
Placebo Comparator: Placebo Other: placebo
matching placebo capsules given in 3 divided doses

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women who are at least 18 years old.
  • Diagnosis of painful diabetic peripheral neuropathy.
  • Pain on walking.

Exclusion Criteria:

  • Inability to walk 50 feet on a flat surface.
  • Pain on walking due to conditions other than diabetic peripheral neuropathy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01474772

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021

  Show 47 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01474772     History of Changes
Other Study ID Numbers: A0081269
Study First Received: November 15, 2011
Last Updated: April 29, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Diabetic Peripheral Neuropathy
Pain on Walking
Pregabalin

Additional relevant MeSH terms:
Peripheral Nervous System Diseases
Demyelinating Diseases
Polyneuropathies
Nerve Compression Syndromes
Neurologic Manifestations
Neurotoxicity Syndromes
Diabetic Neuropathies
Neuromuscular Diseases
Nervous System Diseases
Signs and Symptoms
Poisoning
Substance-Related Disorders
 Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Pregabalin
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anticonvulsants

ClinicalTrials.gov processed this record on May 19, 2013